Maintenance therapy with peginterferon Alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C

Jordi Bruix, Thierry Poynard, Massimo Colombo, Eugene R Schiff, Kelly Burak, Elizabeth J L Heathcote, Thomas Berg, Jorgeluis Poo, Carlos Brandao Mello, Rainer Guenther, Claus Niederau, Ruben Terg, Pierre Bedossa, Navdeep Boparai, Louis H. Griffel, Margaret Burroughs, Clifford A. Brass, Janice K. Albrecht

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Background & Aims: Several studies have reported that low doses of interferon can delay the development of hepatocellular carcinoma (HCC) and progression of chronic hepatitis C. We investigated the incidence of clinical events among participants of the Evaluation of PegIntron in Control of Hepatitis C Cirrhosis (EPIC)3 program. Methods: Data were analyzed from an open-label randomized study of patients with chronic hepatitis C who had failed to respond to interferon alfa plus ribavirin. All patients had compensated cirrhosis with no evidence of HCC. Patients received peginterferon alfa-2b (0.5 μg/kg/week; n = 311) or no treatment (controls, n = 315) for a maximum period of 5 years or until 98 patients had a clinical event (hepatic decompensation, HCC, death, or liver transplantation). The primary measure of efficacy was time until the first clinical event. Results: There was no significant difference in time to first clinical event among patients who received peginterferon alfa-2b compared with controls (hazard ratio [HR], 1.452; 95% confidence interval [CI]: 0.8802.396). There was no decrease in the development of HCC with therapy. The time to disease progression (clinical events or new or enlarged varices) was significantly longer for patients who received peginterferon alfa-2b compared with controls (HR, 1.564; 95% CI: 1.1302.166). In a prospectively defined subanalysis of patients with baseline portal hypertension, peginterferon alfa-2b significantly increased the time to first clinical event compared with controls (P = .016). There were no new safety observations. Conclusions: Maintenance therapy with peginterferon alfa-2b is not warranted in all patients and does not prevent HCC. However, there is a potential clinical benefit of long-term suppressive therapy in patients with preexisting portal hypertension.

Original languageEnglish
Pages (from-to)1990-1999
Number of pages10
JournalGastroenterology
Volume140
Issue number7
DOIs
StatePublished - Jun 1 2011

Fingerprint

Chronic Hepatitis C
Hepatocellular Carcinoma
Safety Management
Therapeutics
Portal Hypertension
Fibrosis
Confidence Intervals
peginterferon alfa-2b
Ribavirin
Varicose Veins
Hepatitis C
Interferon-alpha
Liver Transplantation
Interferons
Disease Progression
Safety
Liver
Incidence

Keywords

  • Clinical Trial
  • EPIC Program
  • Evaluation of PegIntron in Control of Hepatitis C Cirrhosis Program
  • Liver Cancer

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Maintenance therapy with peginterferon Alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. / Bruix, Jordi; Poynard, Thierry; Colombo, Massimo; Schiff, Eugene R; Burak, Kelly; Heathcote, Elizabeth J L; Berg, Thomas; Poo, Jorgeluis; Mello, Carlos Brandao; Guenther, Rainer; Niederau, Claus; Terg, Ruben; Bedossa, Pierre; Boparai, Navdeep; Griffel, Louis H.; Burroughs, Margaret; Brass, Clifford A.; Albrecht, Janice K.

In: Gastroenterology, Vol. 140, No. 7, 01.06.2011, p. 1990-1999.

Research output: Contribution to journalArticle

Bruix, J, Poynard, T, Colombo, M, Schiff, ER, Burak, K, Heathcote, EJL, Berg, T, Poo, J, Mello, CB, Guenther, R, Niederau, C, Terg, R, Bedossa, P, Boparai, N, Griffel, LH, Burroughs, M, Brass, CA & Albrecht, JK 2011, 'Maintenance therapy with peginterferon Alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C', Gastroenterology, vol. 140, no. 7, pp. 1990-1999. https://doi.org/10.1053/j.gastro.2011.03.010
Bruix, Jordi ; Poynard, Thierry ; Colombo, Massimo ; Schiff, Eugene R ; Burak, Kelly ; Heathcote, Elizabeth J L ; Berg, Thomas ; Poo, Jorgeluis ; Mello, Carlos Brandao ; Guenther, Rainer ; Niederau, Claus ; Terg, Ruben ; Bedossa, Pierre ; Boparai, Navdeep ; Griffel, Louis H. ; Burroughs, Margaret ; Brass, Clifford A. ; Albrecht, Janice K. / Maintenance therapy with peginterferon Alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. In: Gastroenterology. 2011 ; Vol. 140, No. 7. pp. 1990-1999.
@article{8df68fc078cf4f938a4ebebf579a024c,
title = "Maintenance therapy with peginterferon Alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C",
abstract = "Background & Aims: Several studies have reported that low doses of interferon can delay the development of hepatocellular carcinoma (HCC) and progression of chronic hepatitis C. We investigated the incidence of clinical events among participants of the Evaluation of PegIntron in Control of Hepatitis C Cirrhosis (EPIC)3 program. Methods: Data were analyzed from an open-label randomized study of patients with chronic hepatitis C who had failed to respond to interferon alfa plus ribavirin. All patients had compensated cirrhosis with no evidence of HCC. Patients received peginterferon alfa-2b (0.5 μg/kg/week; n = 311) or no treatment (controls, n = 315) for a maximum period of 5 years or until 98 patients had a clinical event (hepatic decompensation, HCC, death, or liver transplantation). The primary measure of efficacy was time until the first clinical event. Results: There was no significant difference in time to first clinical event among patients who received peginterferon alfa-2b compared with controls (hazard ratio [HR], 1.452; 95{\%} confidence interval [CI]: 0.8802.396). There was no decrease in the development of HCC with therapy. The time to disease progression (clinical events or new or enlarged varices) was significantly longer for patients who received peginterferon alfa-2b compared with controls (HR, 1.564; 95{\%} CI: 1.1302.166). In a prospectively defined subanalysis of patients with baseline portal hypertension, peginterferon alfa-2b significantly increased the time to first clinical event compared with controls (P = .016). There were no new safety observations. Conclusions: Maintenance therapy with peginterferon alfa-2b is not warranted in all patients and does not prevent HCC. However, there is a potential clinical benefit of long-term suppressive therapy in patients with preexisting portal hypertension.",
keywords = "Clinical Trial, EPIC Program, Evaluation of PegIntron in Control of Hepatitis C Cirrhosis Program, Liver Cancer",
author = "Jordi Bruix and Thierry Poynard and Massimo Colombo and Schiff, {Eugene R} and Kelly Burak and Heathcote, {Elizabeth J L} and Thomas Berg and Jorgeluis Poo and Mello, {Carlos Brandao} and Rainer Guenther and Claus Niederau and Ruben Terg and Pierre Bedossa and Navdeep Boparai and Griffel, {Louis H.} and Margaret Burroughs and Brass, {Clifford A.} and Albrecht, {Janice K.}",
year = "2011",
month = "6",
day = "1",
doi = "10.1053/j.gastro.2011.03.010",
language = "English",
volume = "140",
pages = "1990--1999",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "7",

}

TY - JOUR

T1 - Maintenance therapy with peginterferon Alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C

AU - Bruix, Jordi

AU - Poynard, Thierry

AU - Colombo, Massimo

AU - Schiff, Eugene R

AU - Burak, Kelly

AU - Heathcote, Elizabeth J L

AU - Berg, Thomas

AU - Poo, Jorgeluis

AU - Mello, Carlos Brandao

AU - Guenther, Rainer

AU - Niederau, Claus

AU - Terg, Ruben

AU - Bedossa, Pierre

AU - Boparai, Navdeep

AU - Griffel, Louis H.

AU - Burroughs, Margaret

AU - Brass, Clifford A.

AU - Albrecht, Janice K.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Background & Aims: Several studies have reported that low doses of interferon can delay the development of hepatocellular carcinoma (HCC) and progression of chronic hepatitis C. We investigated the incidence of clinical events among participants of the Evaluation of PegIntron in Control of Hepatitis C Cirrhosis (EPIC)3 program. Methods: Data were analyzed from an open-label randomized study of patients with chronic hepatitis C who had failed to respond to interferon alfa plus ribavirin. All patients had compensated cirrhosis with no evidence of HCC. Patients received peginterferon alfa-2b (0.5 μg/kg/week; n = 311) or no treatment (controls, n = 315) for a maximum period of 5 years or until 98 patients had a clinical event (hepatic decompensation, HCC, death, or liver transplantation). The primary measure of efficacy was time until the first clinical event. Results: There was no significant difference in time to first clinical event among patients who received peginterferon alfa-2b compared with controls (hazard ratio [HR], 1.452; 95% confidence interval [CI]: 0.8802.396). There was no decrease in the development of HCC with therapy. The time to disease progression (clinical events or new or enlarged varices) was significantly longer for patients who received peginterferon alfa-2b compared with controls (HR, 1.564; 95% CI: 1.1302.166). In a prospectively defined subanalysis of patients with baseline portal hypertension, peginterferon alfa-2b significantly increased the time to first clinical event compared with controls (P = .016). There were no new safety observations. Conclusions: Maintenance therapy with peginterferon alfa-2b is not warranted in all patients and does not prevent HCC. However, there is a potential clinical benefit of long-term suppressive therapy in patients with preexisting portal hypertension.

AB - Background & Aims: Several studies have reported that low doses of interferon can delay the development of hepatocellular carcinoma (HCC) and progression of chronic hepatitis C. We investigated the incidence of clinical events among participants of the Evaluation of PegIntron in Control of Hepatitis C Cirrhosis (EPIC)3 program. Methods: Data were analyzed from an open-label randomized study of patients with chronic hepatitis C who had failed to respond to interferon alfa plus ribavirin. All patients had compensated cirrhosis with no evidence of HCC. Patients received peginterferon alfa-2b (0.5 μg/kg/week; n = 311) or no treatment (controls, n = 315) for a maximum period of 5 years or until 98 patients had a clinical event (hepatic decompensation, HCC, death, or liver transplantation). The primary measure of efficacy was time until the first clinical event. Results: There was no significant difference in time to first clinical event among patients who received peginterferon alfa-2b compared with controls (hazard ratio [HR], 1.452; 95% confidence interval [CI]: 0.8802.396). There was no decrease in the development of HCC with therapy. The time to disease progression (clinical events or new or enlarged varices) was significantly longer for patients who received peginterferon alfa-2b compared with controls (HR, 1.564; 95% CI: 1.1302.166). In a prospectively defined subanalysis of patients with baseline portal hypertension, peginterferon alfa-2b significantly increased the time to first clinical event compared with controls (P = .016). There were no new safety observations. Conclusions: Maintenance therapy with peginterferon alfa-2b is not warranted in all patients and does not prevent HCC. However, there is a potential clinical benefit of long-term suppressive therapy in patients with preexisting portal hypertension.

KW - Clinical Trial

KW - EPIC Program

KW - Evaluation of PegIntron in Control of Hepatitis C Cirrhosis Program

KW - Liver Cancer

UR - http://www.scopus.com/inward/record.url?scp=79958177731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958177731&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2011.03.010

DO - 10.1053/j.gastro.2011.03.010

M3 - Article

C2 - 21419770

AN - SCOPUS:79958177731

VL - 140

SP - 1990

EP - 1999

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 7

ER -